ZNTL: Azenosertib nears pivotal data in ovarian cancer, with FDA backing and robust financial runway
Azenosertib is advancing in late-stage trials for platinum-resistant ovarian cancer, with strong FDA support and a differentiated safety profile. Expansion into earlier lines and other tumor types is under evaluation, while commercial and financial preparations ensure readiness for upcoming data an…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.